Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of SRN-001 in Healthy Participants
NCT05984992Phase 1Completed
- Sponsor
- siRNAgen Therapeutics
- Start
- Sep 2023
- Primary completion
- Mar 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing SRN-001 with Placebo (2 arms). Primary endpoints: Number of participants with treatment-emergent adverse events at 4 weeks and Number of participants with serious adverse events at 4 weeks. Started Sep 2023; status: completed.
02
Drugs
SRN-001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05984992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05984992.